Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Genital Diseases 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1Advanced Solid Tumor 1Advanced Nonhematologic Malignancies 1

Interventions

Fulvestrant 9Alpelisib 6Letrozole 4serabelisib 3ribociclib 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3Cetuximab 3sapanisertib 2pembrolizumab 2parsaclisib 2binimetinib 2Topotecan 2NVP-BKM120 2Irinotecan 2Gemcitabine 2venetoclax 1tipifarnib 1talazoparib 1sotorasib 1ruxolitinib 1olaparib 1obinutuzumab 1niraparib 1lorlatinib 1liposomal doxorubicin 1gedatolisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Hereditary Sensory and Autonomic Neuropathies × serabelisib × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

Phase 2 Recruiting
40 enrolled
Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT01449370 2017-03-09

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Takeda

Phase 1 Completed
125 enrolled 46 charts

Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡